Exelixis (NASDAQ:EXEL) Rating Lowered to Strong Sell at Zacks Research

Exelixis (NASDAQ:EXEL) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Monday,Zacks.com reports. Zacks Research also issued estimates for Exelixis’ Q4 2027 earnings at $1.00 EPS, Q1 2028 earnings at $0.97 EPS and Q2 2028 earnings at $0.99 EPS.

EXEL has been the topic of a number of other reports. Wells Fargo & Company lifted their target price on Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday, July 13th. Stifel Nicolaus upped their price target on Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Citizens Jmp lifted their price objective on Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Wednesday, June 24th. Finally, Royal Bank Of Canada boosted their price objective on Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $49.50.

Exelixis Price Performance

NASDAQ EXEL opened at $56.00 on Monday. The company’s fifty day moving average is $53.95 and its two-hundred day moving average is $47.76. Exelixis has a 52-week low of $33.76 and a 52-week high of $57.57. The firm has a market capitalization of $14.08 billion, a price-to-earnings ratio of 18.60, a P/E/G ratio of 1.59 and a beta of 0.44.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. During the same quarter in the prior year, the business earned $0.55 earnings per share. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. As a group, sell-side analysts expect that Exelixis will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 32,110 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the sale, the executive vice president directly owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. This represents a 8.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jack L. Wyszomierski sold 3,925 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $50.55, for a total transaction of $198,408.75. Following the sale, the director directly owned 284,384 shares of the company’s stock, valued at approximately $14,375,611.20. The trade was a 1.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 219,170 shares of company stock worth $10,620,641 over the last ninety days. Company insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Exelixis

A number of large investors have recently bought and sold shares of EXEL. Motiv8 Investments LLC acquired a new stake in Exelixis during the 4th quarter valued at $26,000. Cassaday & Co Wealth Management LLC acquired a new position in Exelixis in the first quarter worth $27,000. Western Wealth Management LLC acquired a new position in Exelixis in the first quarter worth $29,000. Acumen Wealth Advisors LLC bought a new stake in shares of Exelixis during the fourth quarter worth $29,000. Finally, Activest Wealth Management bought a new stake in shares of Exelixis during the fourth quarter worth $32,000. 85.27% of the stock is currently owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.